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The aggregation of α-synuclein (α-syn) is considered the key pathogenic event in many
neurological disorders such as Parkinson’s disease (PD), dementia with Lewy bodies and
multiple system atrophy, giving rise to a whole category of neurodegenerative diseases
known as synucleinopathies. Although the molecular basis of α-syn toxicity has not been
precisely elucidated, a great deal of effort has been put into identifying compounds that
could inhibit or even reverse the aggregation process. Previous reports indicated that many
phenolic compounds are potent inhibitors of α-syn aggregation. The aim of the present
study was to assess the anti-aggregating effect of gallic acid (GA) (3,4,5-trihydroxybenzoic
acid), a benzoic acid derivative that belongs to a group of phenolic compounds known
as phenolic acids. By employing an array of biophysical and biochemical techniques and
a cell-viability assay, GA was shown not only to inhibit α-syn fibrillation and toxicity but
also to disaggregate preformed α-syn amyloid fibrils. Interestingly, GA was found to bind
to soluble, non-toxic oligomers with no β-sheet content, and to stabilize their structure.
The binding of GA to the oligomers may represent a potential mechanism of action.
Additionally, by using structure activity relationship data obtained from fourteen structurally
similar benzoic acid derivatives, it was determined that the inhibition of α-syn fibrillation by
GA is related to the number of hydroxyl moieties and their position on the phenyl ring. GA
may represent the starting point for designing new molecules that could be used for the
treatment of PD and related disorders.
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INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder, the
incidence of which rises sharply after the fifth decade of life,
affecting 1.4 and 3.4% of the population at 55 and 75 years
of age, respectively (Wood, 1997). PD affects a region of the
brain known as the substantia nigra, resulting in a dramatic
loss of dopaminergic neurons and a concomitant plummet-
ing in dopamine levels in striatum. As a consequence, PD is
manifested by a plethora of clinical symptoms, with the most
prominent being impaired motor activity, muscle rigidity, and
resting tremor. Neuropathologically, PD is characterized by the
presence of intracellular inclusions known as Lewy bodies (LBs),
the main constituent of which are α-synuclein (α-syn) fibrils
(Spillantini et al., 1997; El-Agnaf et al., 1998). Moreover, accu-
mulated results over the last few decades show that mitochondrial
dysfunction followed by oxidative stress are both associated with
neurodegenerative diseases (Leuner et al., 2007; Schmitt et al.,
2012).
Although α-syn belongs to the family of natively unfolded
proteins, which demonstrate little or no ordered structure, the
protein has the intrinsic propensity to fibrillate, giving rise to
insoluble fibrils similar to the ones detected in LBs (Hashimoto
et al., 1998; Giasson et al., 1999; Conway et al., 2000; Serpell et al.,
2000; Greenbaum et al., 2005). Additionally, five missense muta-
tions in the α-syn gene (SNCA), namely A53T (Polymeropoulos
et al., 1997), A30P (Krüger et al., 1998), E46K (Zarranz et al.,
2004), H50Q (Appel-Cresswell et al., 2013) and G51D (Kiely
et al., 2013), have been linked to severe inherited forms of PD,
while duplications and triplications of SNCA lead to autosomal
dominant PD in a gene dosage-dependent fashion (Singleton
et al., 2003; Ibáñez et al., 2004). Moreover, transgenic animal and
Drosophila models expressing either wild-type or mutant human
α-syn also develop fibrillar inclusions and a Parkinsonian pheno-
type (Feany and Bender, 2000; Masliah et al., 2000; Kahle et al.,
2001; Imai et al., 2011; Cannon et al., 2013). Overexpression of
α-syn, especially its mutant forms, is thought to enhance the
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vulnerability of neurons to DA-induced cell death through an
excessive generation of intracellular ROS (Junn and Mouradian,
2002). Many evidences point to the key role of α-syn in the reg-
ulation and biosynthesis of DA, the loss of α-syn function as a
consequence to its aggregation lead to selective disrupt DA home-
ostasis and negatively affect dopaminergic neuron survival (Perez
et al., 2002). It is noteworthy that the fibrillation of α-syn is
implicated in the development of a series of neurodegenerative
diseases, including multiple system atrophy (MSA) and demen-
tia with Lewy bodies (DLB), which are collectively referred to
as synucleinopathies (Spillantini and Goedert, 2000; Trojanowski
and Lee, 2003). Mitochondrial pathophysiology aggressively pro-
motes neuronal dysfunction and loss of synaptic viability, leading
ultimately to neurodegeneration (Perier and Vila, 2012), and
accumulated evidence from both in vitro and in vivo studies,
postulates a major pathogenic role for a α-syn in mitochondrial
dysfunction, thereby providing a link between protein aggrega-
tion, mitochondrial damage, and neurodegeneration (reviewed
in Camilleri and Vassallo, 2014). Taken together, these findings
indicate a central role for α-syn aggregation in PD pathogene-
sis. α-Syn aggregation proceeds through several key intermediate
stages, with monomeric α-syn first assembling into oligomeric
forms that gradually generate insoluble amyloid fibrils. Because
α-syn aggregation plays a crucial role in PD pathogenesis and
related synucleinopathies, intensive effort has been put into iden-
tifying compounds that could block or even reverse the aggre-
gation process. Over the years, polyphenols, a set of more than
8000 compounds that contain one or more phenolic rings, have
emerged as potent amyloid inhibitors, interfering with the in vitro
fibril assembly of many amyloidogenic proteins including α-syn,
β-amyloid (Aβ), tau-protein and prions (reviewed in Porat et al.,
2006).
Gallic acid (GA) is a phenolic acid. Phenolic acids constitute
a group of compounds, which are derived from benzoic acid and
cinnamic acid, giving rise to hydroxybenzoic acids and hydrocin-
namicacids, respectively. GA (3,4,5-trihydroxybenzoic acid) is a
benzoic acid derivative that can be found in almost all plants,
with the highest GA contents detected in gallnuts, witch hazel,
pomegranate, berries such as blackberry and raspberry, sumac,
tea leaves and oak bark. GA can also be isolated from the roots of
Radix Paeoniae (white-flowered peony), which is commonly used
to treat vascular and liver diseases in traditional Chinese medicine
(Ho andHong, 2011). It has been reported that GA possesses anti-
oxidant (Kim, 2007), anti-inflammatory (Kroes et al., 1992) and
anti-viral (Kreis et al., 1990) properties, and a well-documented
anti-cancer activity (Yang et al., 2000; Liu et al., 2011; Ho et al.,
2013). Recently, GA has been reported to act as a potent anti-
oxidant and free radical scavenger in a rat PDmodel (Sameri et al.,
2011). Additionally, GAwas shown to efficiently inhibit α-syn and
Aβ aggregation and toxicity in vitro (Bastianetto et al., 2006; Di
Giovanni et al., 2010).
The aim of the present study was to systematically assess the
ability of GA to (a) inhibit α-syn oligomerization and fibrillation,
(b) block α-syn-induced toxicity and (c) disaggregate preformed
α-syn fibrils. To gain insight of the mechanism of action of
GA against α-syn aggregation and toxicity and to establish a
structure-activity relationship, we assessed the anti-fibrillogenic
effect of eleven different hydroxybenzoic acid derivatives with
chemical structures similar to GA. The selection of the phe-
nolic acids was based on the number of the hydroxyl moieties
attached to the phenyl ring. To further investigate the role of
hydroxyl groups in the inhibitory activity of phenolic acids, we
also included and assessed the effect of three different benzoic
acid derivatives that have fluorides and methoxy groups instead
of hydroxyl moieties.
MATERIALS AND METHODS
EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN α-SYN
TheGST-α-syn fusion construct in pGEX-4T1 vector (kindly pro-
vided by Dr. Hyangshuk Rhim, The Catholic University College
of Medicine, Seoul, Korea) was inserted into E.coli BL21bacteria
for protein expression by heat shock transformation. The trans-
formed bacteria were grown in LB medium supplemented with
0.1mg/ml ampicillin at 37◦C in an orbital shaker until the OD600
was 0.5. GST-α-syn expression was then induced by adding
0.5mM IPTG (Sigma-Aldrich Chemie GmbH, Germany), and the
culture was incubated for 2 h at 37◦C. The cells were harvested by
15min centrifugation at 9000 × g (Beckman Coulter, Avanti J-26
XP). The pellets were resuspended in lysis buffer (50mM Tris-
HCl, pH 7.4, 150mMNaCl, 2mMEDTA, 1%NP-40, 0.1%DTT),
and the lysed pellets were shaken for 10min at room temperature.
The lysed pellets were then subjected to 6 freeze-thaw cycles in liq-
uid nitrogen and a 37◦C water bath. The lysates were centrifuged
further at 27,000 × g for 15min. The supernatant was kept for
purification with affinity chromatography. Glutathione sepharose
4B beads (Amersham, Sweden) were centrifuged at 500 × g at
4◦C for 8min to remove the storage buffer. The beads were then
washed with 20ml cold PBS followed by spinning at 500 × g at
4◦C for 10min. The cell lysate was mixed with the washed beads
and incubated for 1 h at room temperature, followed by centrifu-
gation at 500 × g at 4◦C for 8min. The beads were then washed
twice with column washing buffer (50mM Tris-HCl, 150mM
NaCl, 10mMEDTA, 1%Triton X-100, pH 8.0), twice with 50mM
Tris-HCl, pH 8.0 and once with 1X PBS. The washed beads were
resuspended in 5ml of 1X PBS. The GST tag, which interacts with
glutathione beads, was cleaved by thrombin (1 unit/μl human
plasma thrombin, Sigma). The thrombin-catalyzed reaction was
incubated overnight at room temperature with continuous mix-
ing. The mixture was then incubated for 5min at 37◦C and
centrifuged for 8min at 500 × g at 4◦C. Benzamidinesepharose
beads (Amersham, Sweden) were used to remove the thrombin
from the solution. Pure α-syn was collected by centrifugation at
500 × g for 8min at 4◦C. The α-syn concentration was estimated
using the BCA assay (Pierce Biotechnology, Rockford, IL).
AGGREGATION OF α-SYN IN VITRO
Stock solutions of the tested compounds (10mM) were prepared
in DMSO. Solutions of lower concentrations were prepared by
diluting the stock solutions to final concentrations of 25–100μM.
The amount of DMSO in the final samples was 1%. Samples of
25μM (unless otherwise stated) α-syn in PBS were aged either
alone or with phenolic acids at various molar ratios (phenolic
acids to protein molar ratios of 4:1, 2:1, and 1:1). The samples
were placed in 1.5ml sterile polypropylene tubes, sealed with
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parafilm and incubated at 37◦C for 5 days with continuous shak-
ing at 800 rpm in a Thermomixer (Eppendorf). Samples were
collected at regular time points. Thioflavin-S (Th-S) fluorescence
was measured immediately, while the rest of the samples were
stored at −80◦C until needed for further analysis.
THIOFLAVIN-S (TH-S) FLUORESCENCE ASSAY
α-Syn fibril formation was monitored by Th-S binding. Th-S is
a fluorescent dye that interacts with fibrils in a β-sheet struc-
ture. Each sample (10μl) was mixed with 40μl of Th-S (25μM)
in PBS. Fluorescence was measured in a 384-well, non-treated,
black micro-well plate (Nunc, Denmark) using a Victor X3 2030
(Perkin Elmer) microplate reader with excitation and emission
wavelengths of 450 and 486 nm, respectively. To allow for back-
ground fluorescence, the fluorescence intensity of a blank well
containing only PBS solution was subtracted from all readings.
TRANSMISSION ELECTRON MICROSCOPY (TEM)
Electron microscopy images were produced from α-syn aged in
the presence or absence of GA. The samples (5μL) were deposited
on Formvar-coated 400mesh copper grids, fixed briefly with 0.5%
glutaraldehyde (5μl), negatively stained with 2% uranyl acetate
(Sigma-Aldrich) and examined in a Philips CM-10 TEM electron
microscope.
IMMUNOBLOTTING
Samples (20 ng) of α-syn incubated alone or with GA were mixed
with loading sample buffer (250mM Tris-HCl, pH 6.8, 30% glyc-
erol, 0.02% bromophenol blue) without SDS or boiling and then
separated on 1mm 15% SDS-PAGE gels. The separated pro-
teins were transferred to nitrocellulose membranes (0.45μm,
WhatmanGmbh-Germany) at 90V for 80min. The membranes
were boiled for 5min in PBS and then blocked for 1 h with
5% non-fat milk prepared in PBS-Tween-20 (0.05% PBST). The
membranes were incubated overnight at 4◦C with the primary
antibody, namely the mouse monoclonal anti-α-syn (211) that
recognizes human α-syn (121–125) (Santa Cruz Biotechnology,
USA), at a dilution of 1:1000. The membranes were then washed
several times with PBST, followed by incubation with HRP-
conjugated goat anti-mouse antibody (Dako Ltd., Ely, UK) at
a dilution of 1:70,000 for 60min at room temperature and
gentle agitation. The membranes were then extensively washed
for 25min. The immunoreactive bands were visualized with a
SuperSignal West FemtoChemiluminescent Substrate Kit (Pierce,
Rockford, USA) according to the manufacturer’s instructions.
IMMUNOASSAY FOR MEASURING OLIGOMERIC α-SYN
A384-well ELISA plate (NuncMaxisorb,Nunc, Denmark) was
coated with 1μg/ml of non-biotinylated mouse monoclonal
anti-α-syn antibody [mAb, 211—recognizes amino acid residues
121–125 of human α-syn (Santa Cruz Biotechnology, California,
USA)]diluted in 200mMNaHCO3, pH 9.6 (50μl/well) and incu-
bated overnight at 4◦C. The plate was then washed 4 times with
PBST and blocked with 100μl/well of blocking buffer (5% gelatin
from cold water fish skin, 0.05% Tween 20 in 1X PBS pH 7.4) for
2 h at 37◦C. After washing 4 times with PBST, 50μl of the samples
were dispensed in each well, and each sample was tested in
duplicate. The plates were then incubated at 37◦C for another 3 h.
After washing 4 times with PBST, 50μl of biotinylated 211 anti-
body diluted in blocking buffer to a concentration of 0.4μg/ml
was added and incubated at 37◦C for 2 h. The wells were washed
4 times with PBST and incubated with 50μl/well of Extravidin-
Peroxidase (Sigma-Aldrich, GmbH- Germany) diluted 1:7500 in
blocking buffer and incubated for 1 h at 37◦C. The wells were
then washed 4 times with PBST before adding SuperSignal ELISA
Femto Maximum Sensitivity Substrate (Pierce Biotechnology,
Rockford, USA) (50μL/well). The chemiluminescence in relative
light units was immediately measured using amicroplate reader
(Perkin Elmer).
CULTURE OF BE (2)-M17 HUMAN NEUROBLASTOMA CELLS
BE (2)-M17 human neuroblastoma cells were routinely cul-
tured in Dulbecco’s MEM/Nutrient Mix F-12 (1:1) (Gibco BRL,
Rockville, MD) supplemented with 15% fetal bovine serum
and 1% penicillin-streptomycin (100 U/ml penicillin, 100mg/ml
streptomycin). The cells were maintained at 37◦C in a humidified
incubator with 5% CO2/95% air.
CELL VIABILITY ASSAY
To evaluate the cell viability of BE (2)-M17 human neuroblastoma
cells treated with α-syn aggregates, the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay
was performed as described previously (Mosmann, 1983). Briefly,
BE (2)-M17 cells in DMEM medium were plated at a density
of 15,000 cells/100μl/well in a 96-well plate. After 24 h, the
medium was replaced with 200μl of OPTI-MEM (Gibco BRL)
serum-free medium containing either α-syn aged in the pres-
ence or absence of GA or pre-aged α-syn incubated with different
concentrations of GA. Samples were diluted in OPTI-MEM to
obtain the desired concentration. Cells were then returned into
the incubator and incubated for 48 h. A total of 20μl of MTT
(6mg/ml) in PBS was added to each well, and the plate was
incubated at 37◦C for 4.5 h. The medium-MTT solution was
removed, cell lysis buffer (100μl/well; 15% (w/v) SDS/50% (v/v)
N,N-dimethylformamide, pH 4.7) was added, and the plate was
incubated overnight at 37◦C. Absorbance values at 590 nm were
determined using a plate reader (Perkin Elmer).
CONGO RED BINDING ASSAY
Congo red (20μM) was dissolvedin PBS (pH 7.4) and fil-
tered through a 0.45μm filter. Samples of α-syn (5μM), aged
alone or with GA at different molar ratios, were mixed with
Congo red (final concentration 5μM), and the reaction sam-
ples were thoroughly mixed. The UV absorbance spectrum was
recorded from 400 to 600 nm in a spectrophotometer (DU-
800, Beckman-Coulter) using 10mm quartz cuvettes (Hellma
Analytics-Germany). Monomeric α-syn and Congo red alone
were used as negative controls.
α-SYN DISAGGREGATION ASSAY
Recombinant α-syn dissolved in sterilized PBS (pH 7.4)
was aggregated at a concentration of 25μM as indicated
above. Briefly, the α-syn samples were placed in 1.5ml sterile
polypropylene tubes sealed with parafilm and incubated at 37◦C
for 5 days, with continuous shaking at 800 rpm in a Thermomixer
(Eppendorf). The resulting aggregated α-syn was incubated either
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alone or with GA at various molar ratios (GA: α-syn molar ratios
6:1, 4:1, and 2:1). It should be noted that for the purpose of the
experiment, the concentration of α-syn was assumed to be the
same as that of the fresh α-syn. The samples were incubated at
37◦C for 3 days on a thermomixer with continuous shaking at
800 rpm. Samples were collected at regular time points, and Th-S
fluorescence was measured immediately.
SEEDING POLYMERIZATION ASSAY
The aggregation of monomeric α-syn with or without seeding
was carried out as described elsewhere (Di Giovanni et al., 2010).
Mature α-syn fibrils were fragmented by sonication to obtain
short fibrils, which were employed as ‘seeds’. Briefly, 100μM
monomeric α-syn was seeded with 2μMseeds and incubated in
the presence or absence of GA (10μM and 50μM) at 37◦C for
6 h with continuous shaking. Fibrillation was monitored by Th-S
binding as described above.
PREPARING WT-α-SYN OLIGOMERS
Recombinant α-syn dissolved in sterilized PBS (pH 7.4) was
aggregated at a concentration of 100μM. Sample was placed in
1.5ml sterile polypropylene tubes, sealed with parafilm and incu-
bated at 37◦C for 2 days, with continuous shaking at 800 rpm in a
Thermomixer (Eppendorf).
NATIVE PAGE
Samples of α-syn oligomers, α-syn: GA oligomers and α-syn
monomers (15 ng), were separated in 3–1% Bis-Tris Native PAGE
gel (Novox, Life technologies) according to the manufacturer’s
instructions. The separated proteins were transferred to PVDF
membrane (0.45μm, Thermo Scientific) at 100V for 120min,
after soaking the methanol for 30 s, and followed by soaking in
1x methanol free transfer buffer for 10min. The membrane then
blocked for 1 h with 5% non-fat milk prepared in PBS-Tween-20
(0.05% PBST). The membrane were incubated overnight at 4◦C
with the primary antibody, namely the mouse monoclonal anti-
α-syn (211) that recognizes human α-syn (121–125) (Santa Cruz
Biotechnology, USA), at a dilution of 1:1000. The membranes
were then washed several times with PBST, followed by incuba-
tion with HRP-conjugated goat anti-mouse antibody (Dako Ltd.,
Ely, UK) at a dilution of 1:120,000 for 60min at room tempera-
ture and gentle agitation. The membranes were then extensively
washed for 25min. The immunoreactive bands were visual-
ized with a SuperSignal West FemtoChemiluminescent Substrate
Kit (Pierce, Rockford, USA) according to the manufacturer’s
instructions.
SIZE EXCLUSION CHROMATOGRAPHY (SEC) FOR SEPARATING α-SYN
OLIGOMERS AND MONOMERS
SECwas carried out using an AKTA FPLC system (GEHealthcare-
Sweden) and a superdex 200 column at 4◦C, in order to separate
the oligomers generated from the aggregation of α-syn with GA
(GA: α-syn molar ratio of 4:1). Monomeric α-syn at a concen-
tration of 100μM was aggregated in the presence of GA for 5
days as described above. At the end of the aggregation process, the
sample was centrifuged for 45min at 14,000× g at 4◦C generating
a supernatant free from insoluble material. Prior to injecting 80%
of the generated supernatant, the column was thoroughly equili-
brated with SEC running buffer (1 × PBS, pH 7.4) and the flow
rate was set to 0.1ml/min (0.5ml/fraction). α-Syn elution was
monitored at absorbance wavelengths of 215, 254, and 280 nm.
To determine the elution time of monomeric α-syn, molecular
weight standards (ferritin 440 kDa, aldolase 171 kDa, abmumin
68 kDa and chymotrypsinogen A 25 kDa) and monomeric α-syn
were co-injected into the column and eluted at the same condi-
tions mentioned above. The fractions eluting between 7-9ml CV
were combined and labeled as oligomers (sample P1), whereas the
fractions eluting in the 13–15ml CV were combined and labeled
as monomers (sample P2). The P1 and P2 fractions were further
characterized by western blotting and TEM.
UV SCANNING
The P1 and P2 samples, representing the oligomeric and
monomeric fractions of SEC, respectively, were concentrated
using a speed vac (CentriVap, Labconco). Their protein con-
tent concentration was estimated by the BCA assay. The UV
absorbance spectrum was recorded from 200 to 600 nm in a spec-
trophotometer (DU-800, Beckman-Coulter) using 10mm quartz
cuvettes (Hellma Analytics-Germany) and employing equal con-
centrations of both P1 and P2. Fresh monomeric α-syn was used
as negative control.
NMR
For NMR studies, recombinant 15N-labeled α-syn was expressed
and purified as previously described (Eliezer et al., 2001;
Bussell and Eliezer, 2003), resuspended in PBS at pH 6.5. Two-
dimensional proton-nitrogen correlation spectra were acquired
for α-syn at 200μM concentration in the absence of GA and in
the presence of increasing GA: α-syn stoichiometries of 0.5:1, 1:1,
2:1, 5:1, and 10:1. Data were collected on a Varian 600MHz Unity
Inova spectrometer equipped with a cold probe.
RESULTS
THE EFFECT OF GA ON α-SYN FIBRIL FORMATION
To investigate the effect of GA on α-syn fibrillation, 25μM of α-
syn was incubated with GA at varyingmolar ratios of GA: α-syn of
4:1, 2:1, and 1:1 for a period of 6 days. GA inhibited the formation
of α-syn fibrils in a concentration-dependent manner as indicated
by the Th-S assay (Figure 1A). Taking into account the lack of Th-
S signal at the 4:1 ratio, GA exhibited an excellent inhibitory effect
on α-syn fibrillation, inhibiting it completely during the 6-day
incubation (Figure 1A). At a 2:1 ratio, GA also suppressed the for-
mation of fibrils to a great extent, and the Th-S signal was detected
only after 4 days of incubation, while after 6 days, GA reduced
the Th-S counts to approximately one fifth of the control counts
(Figure 1A). Even at a 1:1 ratio, GA hindered the fibrillation of
α-syn but to a smaller extent than the other ratios (Figure 1A).
The anti-fibrillogenic activity of GA was further assessed by the
Congo red binding assay. Congo red (CR) is a dye with high affin-
ity for amyloid fibrils. The absorption maximum of CR alone
(5μM) was 490 nm, while when incubated with α-syn amyloid
fibrils, the absorption maximum shifted to 508 nm (Figure 1B).
This shift in the peak absorption wavelength represents the bind-
ing of CR to the β-sheet-rich fibrils. However, this prominent shift
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FIGURE 1 | GA inhibits α-syn fibrillation in a concentration-dependent
manner. (A) Samples of α-syn (25μM) were incubated alone or in the
presence of GA (molar ration of GA: α-syn 4:1, 2:1, 1:1) for 6 days with
continuous shaking at 37◦C. Fibril formation was estimated by Th-S
fluorescence. The assay was performed in triplicate (average of triplicate
measurement ± standard deviation). (B) Congo red binding for samples of
α-syn (25μM) incubated alone or in the presence of GA (molar ratio of GA:
α-syn 4:1, 2:1, 1:1) for 6 days with continuous shaking at 37◦C. Samples of
α-syn (5μM) aged alone or with GA were mixed with Congo red at a final
concentration of 5μM. The reaction samples were thoroughly mixed and
placed in a 10mm quartz cuvette. The UV absorbance spectra were recorded
from 400 to 600 nm. C-F. Electron microscopy images of negatively stained
samples of α-syn (25μM) aged alone or in the presence of GA (molar ratio of
GA: α-syn 4:1, 2:1, 1:1) for 6 days with continuous shaking at 37◦C. (C) Aged
α-syn alone. (D) α-Syn aged in the presence of GA at a molar ratio of GA:
α-syn 4:1. (E) α-Syn aged in the presence of GA at a molar ratio of GA: α-syn
2:1. (F) α-Syn aged in the presence of GA at a molar ratio of GA: α-syn 1:1.
Scale bar, 500 nm.
was not observed for the fresh α-syn sample or when α-syn was
aged in the presence of GA (Figure 1B), indicating that GA inhib-
ited the formation of structures with a β-sheet conformation. In
fact, GA blocked the formation of β-sheets in a dose-dependent
manner, similar to the Th-S results. It was observed that the lower
the GA concentration, the more prominent the peak absorbance
wavelengths shift was (485, 493, and 500 nm for 100, 50, and
25μM GA, respectively). Electron microscopy images also con-
firmed that GA not only affected the extent of fibrillation in a
dose-dependent fashion but also the morphology of α-syn fibrils.
Indeed, instead of forming dense meshes of long fibrils (longer
than 1μm) as observed in aged α-syn alone (Figure 1C), α-syn
aged in the presence of 100μM (Figure 1D) and 50μM of GA
(Figure 1E) generated thin, sheared fibrils that were approxi-
mately 0.1–0.2μm in length. α-Syn aged in the presence of 25μM
GA (Figure 1F) formed longer fibrils (approximately 0.5μm
long), which were arranged in dense networks.
THE EFFECT OF GA ON α-SYN OLIGOMERIZATION (EARLY
AGGREGATES)
To evaluate the effect of GA on α-syn oligomer formation,
samples of α-syn aged alone or in the presence of GA at dif-
ferent molar ratios were assessed for their oligomeric content
by oligomer-specific ELISA and immunoblotting. For the detec-
tion of α-syn oligomeric species in the samples, we employed a
novel ELISA developed in our laboratory (El-Agnaf et al., 2006),
which specifically recognizes the oligomeric species present in the
samples. The ELISA results (Figure 2A) indicated that GA could
only inhibit the formation of α-syn oligomers when employed at
the highest concentration, namely 100μM. Interestingly, at lower
concentrations, GA appeared to enhance α-syn oligomerization
compared to the control (Figure 2A). The samples of α-syn aged
in the presence of 25 and 50μM GA exhibited gradually increas-
ing oligomeric content, which was much higher than the control
(Figure 2A).
Similarly, immunoblotting of the same samples (Figure 2B)
indicated a decrease in the oligomeric species when α-syn
was aged with 100μM GA (Figure 2B), while there was a
characteristic increase in the band corresponding to dimeric
α-syn (Figure 2B). The same sample was also characterized
by the presence of strong monomeric and trimeric (approx-
imately 50 kDa) bands and the absence of the bands corre-
sponding to larger α-syn aggregates with high molecular weight.
However, in the presence of 50 and 25μM GA, the bands
corresponding to oligomeric species were much stronger, with
a concentration-dependent decrease in the bands correspond-
ing to monomeric, dimeric and trimeric species. Additionally,
the intensity of the band corresponding to larger α-syn aggre-
gates increased in a dose-dependent manner. These data indicate
that GA at low concentrations may have the ability to stabilize
α-syn oligomers.
THE EFFECT OF GA ON PREFORMED α-SYN AMYLOID FIBRILS
Given that GA was shown to be such an effective inhibitor of
α-syn fibrillation, we investigated whether it could also reverse
fibrillation. Therefore, 25μM of preformed α-syn fibrils were
incubated at 37◦C in the presence of GA at molar ratios of GA: α-
syn of 6:1, 4:1, and 2:1 for a period of 48 h. By measuring the Th-S
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FIGURE 2 | GA inhibits α-syn oligomerization at a high concentration,
but at lower concentrations it promotes oligomerization. (A) Samples of
α-syn (25μM) aged alone or in the presence of GA at different molar ratios for
6 days with continuous shaking at 37◦C were assessed for their ability to
inhibit the formation of oligomers by the oligomeric ELISA assay. The assay
was performed in duplicate (average of duplicate measurements ± standard
deviations). (B) Immunoblot analysis of the effect of GA on α-syn
oligomerization. Fresh or aged α-syn samples alone or in the presence of GA at
molar ratios of GA: α-syn 1:1, 2:1 and 4:1 incubated for 6 days with continuous
shaking at 37◦C were separated by electrophoresis in a15% SDS-PAGE gel.
Lane 1: fresh α-syn; lane 2: aged α-syn; lane 3: GA: α-syn molar ratio of 4:1,
lane 4: GA:α-syn molar ratio 2:1 and lane 5: GA: α-syn molar ratio 1:1.
fluorescence counts (Figure 3A), we estimated the fibril content
at the indicated time points. At time 0, the Th-S counts were
approximately 8000 for all samples (Figure 3A). The α-syn fib-
rils that were incubated alone continued to aggregate further, as
indicated by the increase in Th-S counts (Figure 3A). However,
the α-syn fibrils that were incubated in the presence of GA disag-
gregated over time as shown by the decrease in the Th-S counts
(Figure 3A). It is noteworthy that after 24 h of incubation, α-
syn fibrils incubated without GA gave approximately 18,000 Th-S
counts, while the fibrils incubated with all tested concentrations
of GA produced less than 2000 Th-S counts (Figure 3A). Thus,
GA disaggregated preformed α-syn fibrils in a dose-dependent
fashion.
After 48 h of incubation, the samples were also tested
for their CR binding (Figure 3B). As expected, α-syn fibrils
incubated in the presence of GA produced spectra with a
peak absorbance wavelength that was slightly shifted com-
pared to the controls, indicating minimal β-sheet content. In
contrast, the fibrils of α-syn that were incubated alone pro-
duced a peak absorbance at 550 nm, indicating a high β-
sheet content (Figure 3B). These findings were confirmed by
EM (Figure 3C). All samples at time 0 were characterized by
the presence of dense meshes of fibrils longer than 0.5μm.
However, the α-syn fibrils incubated in the presence of GA grad-
ually became thinner and shorter and appeared fragmented,
isolated and scarce, unlike the control, which continued to
demonstrate networks of long fibrils (Figure 3C). Furthermore,
similar results were obtained when the experiment was per-
formed using α-syn fibrils after reaching plateau in Th-S assay
(Figure S1).
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FIGURE 3 | GA disaggregates preformed α-syn fibrils in a
concentration-dependent manner. (A) Samples of aggregated α-syn were
incubated for 48 h at 37◦C in the absence or presence of various
concentrations of GA (GA: α-syn 6:1, 4:1, 2:1). The fibril content was then
measured by the Th-S binding assay. The assays were performed in triplicate
(average of triplicate measurements ± standard deviations). (B) Congo red
binding to samples of pre-aged α-syn (25μM) incubated alone or in the
presence of GA (molar ratio of GA: α-syn 6:1, 4:1, 1:1) for 72 h with
continuous shaking at 37◦C. Samples of α-syn (5μM) incubated alone or with
GA at different molar ratios were mixed with Congo red, at a final
concentration of 5μM. The reaction samples were thoroughly mixed and
placed in a 10mm quartz cuvette. The UV absorbance spectra were recorded
from 400 to 600 nm. (C) Electron microscopy images of negatively stained
samples of pre-aged α-syn (25μM) incubated alone or in the presence of GA
for 72 h with continuous shaking at 37◦C. 1. α-Syn aged alone. 2. α-Syn aged
in the presence of GA at a GA: α-syn molar ratio of 6:1. 3. α-Syn aged in the
presence of GA at a GA: α-syn molar ratio of 4:1. 4. α-Syn aged in the
presence of GA at a GA: α-syn molar ratio of 2:1. Scale bar, 500 nm. (D) The
disaggregation of preformed α-syn fibrils by GA generated species that were
less toxic to the cells. The viability of BE (2)-M17 human neuroblastoma cells
was assessed by the MTT assay. The results are expressed as percentages
of the control average (i.e., untreated cells). The α-syn species generated by
72 h incubation of preformed α-syn fibrils in the presence or absence of GA
were added to the cells 48 h prior to MTT addition (average of 3 wells ± SD.
Statistical analysis was performed using two tailed unpaired t-test,
∗∗∗p < 0.001; ∗∗p < 0.01).
To assess whether GA disaggregation of α-syn fibrils was
accompanied by a decrease in α-syn toxicity, we then eval-
uated the toxicity of the α-syn species that resulted from
the disaggregation experiment on human neuroblastoma M17
cells (Figure 3D). The samples were diluted to final α-syn
concentrations of 0.5, 1, and 5μM. Preformed α-syn fib-
rils incubated for 6 days in the absence of GA decreased
cell viability in a dose-dependent manner. However, pre-
formed α-syn fibrils incubated with GA for 6 days gener-
ated species that were less toxic compared to the control.
This trend was most prominent for 5μM α-syn, which, when
incubated in the absence of GA, induced death of 45% of
the cells, but in the presence of GA, cell death was less
than 25%.
THE EFFECT OF GA ON THE SEEDING OF α-SYN AGGREGATION
It has been previously shown that the process of amyloid fibril for-
mation follows a nucleation-dependent polymerization (Jarrett
and Lansbury, 1992). According to this model, soluble species
generated via the nucleation of oligomeric species (nucleation or
lag time phase), which in turn polymerize (polymerization or
growth phase) to generate fibrils, reaching thus a final plateau
known as the equilibrium phase (Harper et al., 1999). Small
aggregates or seeds have been shown to accelerate the nucle-
ation phase of amyloid formation both in vitro and in vivo by a
process known as seeding (Jarrett and Lansbury, 1993; Harper
and Lansbury, 1997; Volpicelli-Daley et al., 2011; Luk et al.,
2012). Given that GA inhibited both α-syn fibrillation and dis-
aggregated preformed α-syn fibrils, we sought to identify the
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effect of this phenolic acid on the seeding of α-syn aggregation.
More specifically, mature α-syn fibrils were fragmented by son-
ication to obtain short fibrils, which were employed as “seeds”
(Figure 4B). These short fibrillar “seeds” were then added to
monomeric α-syn, which was allowed to aggregate as described
above. As expected, the addition of short fibrillar seeds acceler-
ated the fibrillation of α-syn as indicated by the increased Th-S
counts. Indeed, with seeding, the extent of α-syn fibrillation after
6 h of incubation was comparable to the fibrillation of the protein
incubated for 72 h without seeding (Figures 1, 4B, respectively).
In order to assess the effect of GA on the seeding of α-syn
aggregation, 10 and 50μMGA was added to 100μMmonomeric
α-syn containing seeds at a final concentration of 2μM, and the
mixture was incubated with continuous mixing at 37◦C for 6 h.
GA at 50μM inhibited the seeded fibrillation of α-syn by approx-
imately 90% as indicated by the extremely low Th-S counts. At
lower concentrations (10μM), GA also had an inhibitory effect
on the seeded fibrillation of α-syn but to a smaller extent. At
10μM, GA inhibited seeded fibrillation by 40–50% (Figure 4A).
These findings were confirmed by TEM (Figure 4B).
THE EFFECT OF GA ON α-SYN AGGREGATES-INDUCED TOXICITY
It has been reported that the oligomeric intermediates are the
neurotoxic species in the amyloid fibrillation pathway (Allsop
et al., 2001; El-Agnaf et al., 2001, 2006; Vendruscolo et al., 2001;
Walsh et al., 2002; Argyriou et al., 2012; Breydo et al., 2012; Colla
et al., 2012). As described above, at high concentration (4:1),
GA inhibited both early and late aggregate formation, whereas
at low concentrations (2:1 and 1:1), it stabilized α-syn oligomers
(Figure 2A). To determine the effect of GA on toxicity conferred
by α-syn aggregates, a cell-based toxicity assay, the MTT assay,
was conducted with human neuroblastoma M17 cells. The sam-
ples were diluted to final α-syn concentrations of 5 and 0.5μM.
The MTT assay showed that α-syn aged in the absence of GA
decreased cell viability in a dose-dependent manner (Figure 5).
However, when α-syn was aged in the presence of a high con-
centration of GA (4:1), there was visible neuroprotection of the
cells observed (Figure 5). At low concentrations (2:1 and 1:1),
GA exhibited a minor protective effect against α-syn toxicity, pos-
sibly due to the increase in oligomers as demonstrated by the
ELISA results and the immunoblotting analysis (Figures 2A,B,
respectively). Our results clearly demonstrate that GA reduced the
toxicity of α-syn at a high concentration (100μM) by significantly
inhibiting the formation of toxic α-syn oligomers. The toxic-
ity of the oligomers resulted from α-syn: GA 1:4 was compared
with α-syn oligomers prepared in the absence of GA as described
in materials and methods section by MTT assay (Figure 5B).
Both samples were characterized for the presence of oligomers
by SDS PAGE (Figure 5C) and native PAGE (Figure 5D). It
was clear that the oligomers resulting from the incubation of
α-syn with GA were not toxic comparing with oligomers in
absence of GA. Moreover, these oligomers were stable under
FIGURE 4 | GA inhibits the seeded fibrillation of α-syn. (A) Samples
of α-syn (100μM) seeded with short fibrillar α-syn (2μM) were
incubated in the presence or absence of GA at different concentrations
(10–50μM) for 6 h with continuous shaking at 37◦C. The extent of
fibrillation was estimated by the Th-S binding assay. The assays were
performed in triplicate (average of triplicate measurements ± standard
deviations). (B) Electron microscopy images of negatively stained
samples of seeds alone and α-syn+ seeds incubated alone or in the
presence of GA (50μM) for 6 h with continuous shaking at 37◦C. Scale
bar, 1000 nm.
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FIGURE 5 | Effect of GA on the toxicity of aggregated α-syn. (A) The
viability of BE (2)-M17 human neuroblastoma cells was estimated by the
MTT assay. The results are expressed as percentage of the control
average (i.e., untreated cells). The cells were treated with aggregated
α-syn with/without GA for 48 h prior to MTT addition (average of 3
wells ± standard deviation. Statistical analysis was performed using
two-tailed unpaired t-test, ∗∗∗, p < 0.001; ∗, p < 0.05). (B) The viability of
BE (2)-M17 human neuroblastomacells was estimated by the MTT assay.
The results are expressed as percentage of the control average (i.e.,
untreated cells). The cells were treated with α-syn oligomers in absence
or presence of GA for 48 h prior to MTT addition (average of 3 wells ±
standard deviation. (C) Immunoblot analysis of α-syn oligomers generated
in presence or absence of GA, separated by electrophoresis in a 15%
SDS-PAGE gel. (D) Immunoblot analysis of α-syn oligomers generated in
presence or absence of GA, separated by electrophoresis in a 3–12%
Native-PAGE gel.
denaturing conditions (Figure 5C) compared those formed in the
absence of GA.
GA INHIBITION OF α-SYN FIBRILLATION IS MEDIATED VIA BINDING TO
THE INTERMEDIATE SPECIES AND FORMING STABLE OLIGOMERS
The strong inhibitory effect that GA exerted on fibrillation
together with the stimulating effect it had on α-syn oligomer-
ization at lower GA concentrations, prompted us to investigate
further the interaction of GA with α-syn oligomers. For this
purpose, monomeric α-syn (100μM) was aggregated in the pres-
ence of GA (GA: α-syn 4:1). After 5 days of incubation the
samples were centrifuged and the supernatant was injected in a
superdex 200 SE column. The elution volume for monomeric
α-syn was determined by molecular weight standards (Figure
S2A), and was eluted in a peak corresponding to column vol-
ume of 13–15mL (Figure S2B), while oligomeric α-syn eluted in
a peak corresponding to column volume of approximately 7–9ml
(Figure 6A). The fractions corresponding to the oligomeric and
monomeric α-syn peaks were separately pooled together giving
rise to P1 and P2 samples, respectively (Figure 6A), which were
concentrated using a speed vac. The α-syn species in samples
P1 and P2 were characterized by western blotting (Figure 6B).
According to the western blotting results, the oligomers gener-
ated during the incubation of α-syn with GA are stable under
denaturing conditions (Figures 5C, 6B). Electron microscopy of
the same samples indicates the presence of different species of
oligomers in P1 (Figure 6D), in agreement with the imunoblot-
ting results (Figure 6B). In order to detect the incorporated
GA in the P1 and P2 samples, we exploited the property of
GA to produce UV absorbance spectra with two peaks, one at
225 nm and one at 260 nm. In the sample containing GA: α-
syn at 4:1 molar ratio, we detected GA only in the oligomeric
P1 samples (Figure 6C). These findings strongly support the
hypothesis that GA binds to the oligomeric species and stabi-
lizes them. To further evaluate whether GA interacts with α-syn
monomers, we monitered a titration of GA into a solution of
monomeric α-syn using two-dimensional NMR spectroscopy,
which provides signals covering the entire amino acid sequence
of α-syn (Figure 7). At stoichiometries of up to 10:1 GA: α-syn
we observed no significant chemical shift or resonance intensity
changes (Figures S3A–E), confirming that GA does not inter-
act significantly with monomeric α-syn. This result is largely in
agreement with NMR studies of related compounds Entacapone,
Tolcapone and Quercetin (Di Giovanni et al., 2010).
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FIGURE 6 | GA binds to α-syn oligomers (GA: α-syn molar ratio of 4:1). (A)
Gel filtration profile of the 5-day-aggregated α-syn in the presence of GA at a
GA: α-syn molar ratio 4:1 (α-syn concentration= 100μM) using a superdex 200
SE column. P1 sample contains the isolated fractions corresponding to the
oligomeric peak and P2 the isolated fractions corresponding to the monomeric
peak. The elution was monitored at the absorbance wavelength of 215 nm.
(B) Immunoblot analysis of the samples P1 and P2 separated by
electrophoresis in a 15%SDS-PAGE gel. (C)UV absorbance spectra of samples
P1 and P2. The UV absorbance was recorded between 200 and 600nm
employing a 10mm quartz cuvette. (D) Electron microscopy images of
negatively stained samples P1 and P2 of α-syn in the presence of GA (molar
ratio of GA: α-syn 4:1) purified by SEC. Scale bar, 1000 nm.
INVESTIGATING THE STRUCTURE-ACTIVITY RELATIONSHIP OF GA
INHIBITION OF α-SYN FIBRILLATION
To define the most effective molecular scaffolds against α-syn fib-
ril formation and establish a structure-activity relationship for
GA, we exploited the structural diversity of benzoic acid deriva-
tives (i.e., hydroxybenzoic acids). Twelve hydroxybenzoic acids,
including GA, salicylic acid and gentisic acid (see Table 1) were
assessed for their anti-fibrillogenic properties by the Th-S bind-
ing assay (Figure 8). The structure of the tested hydroxybenzoic
acids is characterized by the presence of a phenyl ring that has a
carboxyl group and hydroxyl moieties (OH) attached to the ring
at different positions. The selection of the compounds examined
in the present study was based on the number (between 0 and 3)
and position of the hydroxyl groups attached to the phenyl ring
(see Table 2).
The kinetics of α-syn fibrillation was studied over a period of 5
days in the presence or absence of the phenolic acids. Based on the
Th-S assay results (Figure 8 and Table 3), the effect of the twelve
phenolic acids on α-syn fibrillation varied greatly. The extent of
the inhibition of α-syn fibrillation was ∼ 99% for GA, ∼ 72% for
2,4,6-trihydroxybenzoic acid, ∼ 60% for 3,4-dihydroxybenzoic
acid, ∼ 30% for five compounds including 2,6-dihydroxybenzoic
acid and 4-hydroxybenzoic acid and only 5% for benzoic acid
(see Figure 8 and Table 3). Moreover, three compounds, 2-
hydroxybenzoic acid (salicylic acid), 3-hydroxybenzoic acid and
3,5-dihydroxybenzoic acid, failed to inhibit α-syn fibrillation,
with salicylic acid appearing to enhance the aggregation of α-syn
compared to the control (see Figure 8 and Table 3). By com-
paring the structures of the most effective compounds and the
least effective ones, we conclude that better inhibition of fibril-
lation is observed when there are a large number of hydroxyl
groups (-OH) attached to the phenyl ring of the compound.
Moreover, the positions at which the hydroxyl groups are attached
to the phenyl ring also appear to play a critical role. GA has
hydroxyl groups attached at positions 3 and 5 (see Table 2) and
is much more effective than 2,4,6-trihydroxybenzoic acid, which
also bears three -OH groups but at different positions (Figure 8).
Interestingly, 3,4-dihydroxybenzoic acid, which only lacks an
-OH group at position 5 compared to the very effective GA, is
the third best inhibitor of α-syn fibrillation (Figure 8). Among all
the dihydroxybenzoic acids tested, the ones with -OH groups at
two consecutive positions, i.e., 3,4-dihydroxybenzoic acid (60%
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FIGURE 7 | Analysis of GA binding to monomeric α-syn by NMR
spectroscopy. Proton-Nitrogen correlation (HSQC) spectra of monomeric
α-syn in the presence of increasing ratios of GA: α-syn demonstrating that
there are no significant changes in the positions of the NMR resonances,
indicating the lack of an interaction between GA and monomeric α-syn.
Protein concentration was ca. 200μM.
inhibition) and 2,3-dihydroxybenzoic acid (44% inhibition),
are more potent inhibitors compared to those that have -OH
groups at non-consecutive positions, i.e., 2,5-dihydroxybenzoic
acid (30% inhibition) and 3,5-dihydroxybenzoic acid (0% inhi-
bition) (Figure 8). Additionally, all compounds with one -OH
group, as well as the benzoic acid without a -OH group, failed
to show any inhibitory effect on α-syn aggregation (Figure 8).
To further investigate the significance of the hydroxyl moieties
on the activity of the GA and the other active phenolic acids,
three additional compounds with either fluorides or methoxy
groups rather than hydroxyl groups attached to their phenyl
rings (4-methoxybenzoic acid, 3,4,5-trimethoxybenzoic acid and
3,4,5-trifluorobenzoic acid) (see Table 2) were tested for their
ability to inhibit α-syn fibril formation. As expected, none of
the three tested compounds in any of the three molar ratios
tested (compound: α-syn 4:1, 2:1, and 1:1) could inhibit α-syn
fibrillation (Figure 8). This finding provides additional support
for the importance of the presence of the hydroxyl group in the
phenyl ring.
Table 1 | Description and names of the tested benzoic acid
derivatives.
Name of compound MW
Benzoic acid 122.12















The formation of amyloid aggregates has long been considered
responsible for the pathogenesis of several neurodegenerative dis-
orders (Taylor et al., 2002; Dorval and Fraser, 2007; Vekrellis et al.,
2011). Although amyloidogenic proteins, such as α-syn, are usu-
ally found unfolded in their native state (Uversky, 2008; Fauvet
et al., 2012), in which they are soluble and non-toxic, they can
undergo misfolding resulting in the formation of insoluble aggre-
gates (Seidler et al., 1996; Veldman et al., 1998; Irvine et al., 2008;
Kahle, 2008; Stefanis, 2012). These aggregates deposit in various
regions of the brain, constituting the main neuropathological fea-
ture of several neurodegenerative diseases such as PD, DLB, MSA
and approximately the 50% of Alzheimer’s disease cases. In the
case of α-syn, pathological, biochemical, genetic and animalmod-
eling studies provide compelling evidence that α-syn aggregation
plays a pivotal role in the pathogenesis of PD and related synu-
cleinopathies. As a consequence, the identification of compounds
that can block or reverse the aggregation process of α-syn is
considered a vital therapeutic strategy against these diseases.
To this end, we assessed the effect of the phenolic compound
GA (3,4,5-trihydroxybenzoic acid) on α-syn aggregation and tox-
icity, and we established a structure-activity relationship for GA.
By employing an array of biophysical and biochemical techniques,
we showed that at a high concentration (100μM, represented
by the molar ratio 4:1), GA exerts significant inhibitory effect
on both α-syn fibrillation (Figures 1A,B) and oligomerization
(Figures 2A,B), as well as seeded fibrillation of α-syn (Figure 4A).
In accordance with these findings, TEM images revealed that α-
syn in the presence of GA at high concentration only formed a few
short, thin fibrils that had a fragmented appearance (Figure 1D)
accounting for the low Th-S counts (Figure 1A) and the minor
wavelength shift in the CR binding assay (Figure 1B). At lower
GA concentrations (especially at 1:1 molar ratio), however, the
ability of the GA to inhibit α-syn fibrillation was less dramatic
and accompanied by a striking increase in the oligomeric content
(Figure 2A), indicating GAmay stabilize the oligomeric structure.
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FIGURE 8 | Effect of different benzoic acid derivatives (phenolic acids, PA)
and the effect of methoxy and fluoro groups in benzoic acid derivatives
on α-syn fibrillation. Samples of α-syn (25μM) were incubated alone or in
the presence of different benzoic acid derivatives (PA: α-syn molar ratios of
4:1, 2:1, 1:1) for 6 days with continuous shaking at 37◦C. The fibril formation
was measured by the Th-S binding assay and expressed as a percentage of
the fibril content of α-syn aged alone. The assay was performed in triplicate
(average of triplicate measurements ± standard deviations).
Size exclusion chromatography combined with UV spectroscopy
for detection of the incorporated GA in α-syn confirmed that GA
binds to α-syn oligomers (Figure 6C). Furthermore, GA was able
to disaggregate preformed α-syn fibrils (Figures 3A–C), generat-
ing species that possessed a decreased β-sheet content (Figure 3B)
and were less toxic to the cells (Figure 3D). Previous studies have
also shown that the flavonoid baicalein, as well as other antioxi-
dant compounds inhibit α-syn fibrillation and disaggregate pre-
aggregated fibrils (Zhu et al., 2004; Ono and Yamada, 2006). GA
was also shown to alleviate α-syn aggregates associated-toxicity in
neuroblastoma M17 cells (Figures 5A,B).
These results are in agreement with previous studies indi-
cating that GA possesses anti-fibrillation, oligomer-stabilizing
and neuroprotective properties against α-syn and Aβ cytotoxic-
ity (Di Giovanni et al., 2010). Indeed, GA was shown to stabilize
biotinylated Aβ1–42 oligomers (Levine et al., 2012) and to inhibit
the in vitro conversion of low molecular weight Aβ1–42 protofib-
rils into fibrils by 50% (Di Giovanni et al., 2010). Additionally,
GA was reported to block the fibrillation of α-syn in vitro and to
suppress the ability of short α-syn fibrils to seed the aggregation
of monomeric α-syn (Di Giovanni et al., 2010). Furthermore, GA
exerts a neuroprotective effect on cells against the cytotoxicity of
α-syn and Aβ1–42 (Di Giovanni et al., 2010), possibly due to the
inhibition of the amyloid aggregation but potentially also due to
the anti-inflammatory (Kim et al., 2011), anti-oxidant (Ban et al.,
2008; Hong et al., 2012) and anti-apoptotic properties it possesses
(Hong et al., 2012).
Based on our findings using both SEC and NMR, as well as
previous reports, GA inhibits α-syn fibrillation not by interact-
ing with the monomeric α-syn - similar to many other phenolic
compounds (reviewed in Porat et al., 2006)-, and preventing
it from polymerizing, but rather by stabilizing the structure of
oligomeric α-syn (Figures 2B, 6C) which appears to be non-toxic
(Figure 5). These findings are in accordance with previous stud-
ies indicating that polyphenolic compounds, such as baicalein,
curcumin and epigallocatechin gallate (EGCG) induce the for-
mation of soluble, non-toxic oligomers (Zhu et al., 2004; Masuda
et al., 2006). From a therapeutic point of view, this represents a
major advantage, as GA may not interfere with the physiolog-
ical function of the monomeric α-syn (Wagner et al., 2013). It
has been reported that phenolic compounds such as curcumin
inhibit Aβ aggregation due to conformation-dependent binding
(Yang et al., 2005). Consistent with this model of inhibition, GA
also inhibited the seeding ability of short fibrillar α-syn. Although
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Table 2 | The compounds were divided into four groups based on the number of hydroxyl groups attached to the phenyl ring.





















the presence of oligomers can be transient as they assemble into
fibrils (Kaylor et al., 2005; Fink, 2006), there are studies reveal-
ing that in the presence of the polyphenolic compound EGCG,
they can shift off-pathway from fibrillation (Ehrnhoefer et al.,
2008). Indeed, EGCG was shown to promote the formation of
less toxic oligomers that were exceedingly stable and incapable of
contributing to the aggregation process (Ehrnhoefer et al., 2008).
As it is also a phenolic compound, GA may interact with α-syn
oligomers by a mechanism similar to that of EGCG, accelerat-
ing the formation of off-pathway oligomers and leading to the
accumulation of non-toxic oligomers and the interruption of the
fibrillation process.
To gain insight into the mechanism of action of GA and
to establish a structure-function relationship for this pheno-
lic acid, we evaluated the effect of various structurally similar
phenolic acids on α-syn fibrillation. The results generated from
this approach point toward a structure-related effect on α-syn
fibrillation in which the better inhibitors were observed to have
a greater number of -OH groups attached to the phenyl ring
that were directly conjugated to the carboxylic acid arm (see
Figure 8). In fact, the ranking of the anti-fibrillogenic potency
of all the tested phenolic compounds could be represented
as follows: trihydroxybenzoic acid > dihydroxybenzoic acid >
monohydroxybenzoic acid = benzoic acid. This finding is in
accordance with previous studies indicating that the potency of
certain polyphenolic compounds to inhibit and disaggregate α-
syn oligomers correlates with the number of vicinal -OH groups
present on a single phenyl ring (Masuda et al., 2006; Caruana
et al., 2011). The significance of the presence of the hydroxyl
group on the phenyl ring was further stressed by the fact that
the compounds that possess appendages other than hydroxyl
groups on the phenyl rings failed to inhibit α-syn aggregation.
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Table 3 | Summary of Th-S results showing the percentage of
inhibition of fibril formation comparing with number of OH groups
around the phenyl ring.
Symbol Compound OH group Inhibition % of
α-syn aggregation
PA1 3,4,5-trihydroxybenzoic acid 3 99
PA2 2,4,6-trihydroxybenzoic acid 3 72
PA3 2,3-dihydroxybenzoic acid 2 44
PA4 2,4-dihydroxybenzoic acid 2 35
PA5 2,5-dihydroxybenzoic acid 2 30
PA6 2,6-dihydroxybenzoic acid 2 16
PA7 3,4-dihydroxybenzoic acid 2 60
PA8 3,5-dihydroxybenzoic acid 2 0
PA9 2-hydroxybenzoic acid 1 0
PA10 3-Hydroxybenzoic acid 1 0
PA11 4-Hydroxybenzoic acid 1 9
PA12 Benzoic acid 0 5
PA13 4-methoxybenzoic acid 0 0
PA14 3,4,5-trimethoxybenzoic acid 0 0
PA15 3,4,5-trifluorobenzoic acid 0 0
At this point, it is more than an idle speculation to suggest
that the inhibition capacity of the phenolic compounds tested
is not only dependent on the number of hydroxyl moieties but
also on their position and conjugation with respect to the ben-
zoic acid appendage. Comparison of the two trihydroxybenzoic
acids tested in this study, GA (3,4,5-trihydroxybenzoic acid) and
2,4,6-trihydroxybenzoic acid, indicates that although both com-
pounds have a total of three -OH groups, the former is a much
more potent inhibitor of α-syn fibrillation compared to the lat-
ter, strongly suggesting that it is not only the total number of
-OH groups present in the molecule but also their position that
is important. Additionally, comparison of the dihydroxybenzoic
acids employed in the present study reveals that the presence of
-OH groups in two consecutive positions and conjugated with
the carboxyl group [e.g., 3,4-dihydroxybenzoic acid (60% inhi-
bition) and 2,3-dihydroxybenzoic acid (44% inhibition)] renders
the compoundsmore active compared to those that have hydroxyl
groups at non-consecutive positions (e.g., 2,5-dihydroxybenzoic
acid (30% inhibition) and 3,5-dihydroxybenzoic acid (0% inhi-
bition) (see Figure 8 and Table 3). The importance of the 4-OH
moiety is emphasized by the fact that of the three hydroxy-
benzoic acids tested, only 4-hydroxybenzoic acid could partially
inhibit α-syn fibrillation. Among the dihydroxybenzoic acids,
3,4-dihydroxybenzoic acid was the most potent of all, inhibiting
fibrillation by 60% (Table 3). Taken as a whole, these data show
that the total number of -OH groups present in the molecule
is important for the compound activity and that the position
of the overall -OH groups also affects activity, with a hydroxyl
group at position 4 appearing to play a significant role. Thus, the
presence of three vicinal hydroxyl groups, as in 3,4,5-trihydroxy
benzoic acid (GA), or the three homo-vicinal groups, as in 2,4,6-
trihydroxy benzoic acid, with one -OH group at position 4,
renders the compounds able to inhibit α-syn fibrillation to a great
extent.
Given that all the compounds tested in this study have a phenyl
ring in their structures, the phenyl structure itself is clearly not
sufficient to inhibit α-syn aggregation. Consequently, the inhibi-
tion ability of such compounds must be achieved by the presence
of additional -OH groups attached to the phenyl ring. The con-
jugated hydroxyl groups with the carboxylic acid appendage can
easily form quinone structures (see Figure S4). It is worth men-
tioning that quinone formation has been previously reported
as the potential mechanism of inhibition of α-syn fibrillation
by the phenolic compound baicalein (Zhu et al., 2004). The
formation of such oxidized derivatives can increase the stabil-
ity of the compound binding to the α-syn fibrils (Taniguchi
et al., 2005), possibly accounting for the increased inhibitory
potency of the compounds with more -OH groups present in
their structures. Quinones are likely to interact with the aro-
matic residues of α-syn, interfering with theirπ-π stacking (Porat
et al., 2006; Ebrahimi and Schluesener, 2012; Hamley, 2012).
Moreover, quinones have a planar orientation that allows them
to align with the hydrophobic groove of α-syn fibrils, which
possess an in-register organization of side chains in the reg-
ular cross-β-sheet structure (Porat et al., 2006; Ebrahimi and
Schluesener, 2012; Hamley, 2012). Therefore, the inhibition of
α-syn fibrillation by GA and 2,4,6-trihydroxybenzoic acid could
be attributed to the combined properties of their three -OH
groups and quinone-forming structures. Based on these results,
we propose a plausible model to interpret the inhibitory and
disassembling effects of GA. Two dominant ligand-protein inter-
actions contribute to inhibitor potency, (a) the dipole-dipole
interactions of the quinone and (b) the dipole-dipole interac-
tions of the diquinone group. The most potent inhibitors, with
3,4,5-trihydroxy and 2,4,6-trihydroxy substitution patterns (GA
and 2,4,6-trihydroxy benzoic acid, respectively), (see Figure S4c),
enable both hydrophobic and dipole-dipole interactions. The π-
π stacking is known to play a role in the binding affinity of
inhibitors to aggregates, increasing the potential for quinone for-
mation of each compound generally leading to increased binding
affinity and, therefore, increased inhibitor potency. Consistent
with this interpretation, ortho- and meta-hydroxybenzoic acid,
as well as benzoic acid (see Figure S4f) showed no inhibition
effect compared to their para- and ortho-paradihydroxy (Figure
S4a) counterparts due to the inability of the former to form
quinone-like ligands (Figures S4f, d).
Although monocyclic compounds such as phenolic acids were
previously shown to be very poor inhibitors of aggregation
(Reinke and Gestwicki, 2007), later studies revealed that mono-
cyclic compounds could suppress amyloid assembly by interact-
ing with oligomers, stabilizing their structure and conformation,
thus inhibiting the transition to β-sheet structures (Levy-Sakin
et al., 2009). It is therefore likely that phenolic acids, especially
GA, act in a similar way, interacting with oligomers and stabilizing
their structure through the -OH groups, preventing the transi-
tion to β-sheet-rich structures. This may explain the increased
oligomeric content detected at lowGA concentrations and the low
β-sheet content of α-syn species generated in the presence of GA.
In summary, we conducted a systematic study of the effect
of GA on α-syn fibrillation, oligomerization and toxicity, and
we concluded that GA inhibits α-syn fibrillation and toxicity by
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stabilizing the non-toxic oligomeric structure of α-syn through
oligomer binding. Our study points toward a structure-related
inhibition, with the number of -OH moieties and their position
around the phenyl ring playing a fundamental role. Based on
the above experimental results, we propose a model to interpret
the inhibitory and disassembling effects of GA derivatives on α-
syn aggregation (see Figure S5). α-Syn aggregation is a sequential
process in which unstructured α-syn monomers undergo con-
formational transition and re-ordering to form oligomers and
then finally amyloid fibrils (routes a → b → c → d, Figure
S5). The analysis of the results obtained from this study shows
that GA derivatives can prolong the nucleation process, suggest-
ing that these scaffolds can bind to unstructured α-syn oligomers
and prevent protein association (Figure S5, route a → f) and/or
slow down the conformational transition to structured oligomers,
the precursors of amyloid fibrils. GA derivatives interact with α-
syn monomers and/or oligomers through π-π stacking, leading
to the formation of an energy barrier that prevents the asso-
ciation of α-syn molecules. Meanwhile, GA derivatives through
their respective quinone oxidation products could induce struc-
tural disruption to the local β-sheet of α-syn fibrils via strong
binding to the β-sheet groove regions of α-syn fibrils, lead-
ing to fibril disaggregation (d → e). It should be noted that,
due to the hydrophobic aromatic nature and planar structure of
quinones, they might interact with α-syn fibrils by relatively non-
specific dipole-dipole interactions with β-sheet-rich side chains.
This binding mode implies that quinones could have a general
inhibitory effect on the aggregation of α-syn.
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